Summary

The 7 major chronic obstructive pulmonary disease markets reached a value of US$ 13,464.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 18,551.6 Million by 2034, exhibiting a growth rate (CAGR) of 2.96% during 2024-2034.

The chronic obstructive pulmonary disease market has been comprehensively analyzed in IMARC's new report titled "Chronic Obstructive Pulmonary Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic obstructive pulmonary disease (COPD) refers to a chronic respiratory disorder characterized by persistent airflow limitation due to the inflammation of airways and destruction of lung tissue. The most common symptoms of the ailment include shortness of breath, wheezing, chest tightness, chronic cough, excess mucus production, etc. These indications can make it difficult for individuals with COPD to breathe, leading to fatigue, difficulty with physical activity, and reduced quality of life. In advanced stages, COPD can also cause weight loss, depression, and other systemic effects. The diagnosis of the ailment typically involves a combination of medical history, physical examination, lung function tests, and imaging studies. The medical history may include questions about the symptoms, smoking, exposure to environmental irritants, and family history of lung disease. Numerous imaging procedures, such as chest X-rays and CT scans, help identify structural abnormalities in the lungs. In some cases, the healthcare professional may also perform a blood test to evaluate other potential causes of the symptoms.

The increasing incidences of prolonged exposure to lung irritants like tobacco smoke and air pollutants, which damage the lungs by causing inflammation as well as narrowing of the airways, are primarily driving the chronic obstructive pulmonary disease market. In addition to this, the rising prevalence of several associated risk factors, such as exposure to chemical fumes, genetic predisposition, certain respiratory infections, including pneumonia and bronchitis, etc., is also bolstering the market growth. Furthermore, the widespread adoption of numerous medications, such as bronchodilators, corticosteroids, phosphodiesterase-4 inhibitors, etc., to open the airways, reduce inflammation, and improve lung functioning is acting as another growth-inducing factor. Besides this, the escalating utilization of lung volume reduction surgery (LVRS) for treating selected patients with severe COPD who have significant emphysema is further creating a positive outlook for the market. The LVRS procedure involves removing portions of damaged lung tissue, which helps to increase the elasticity of remaining lung tissues and enhances breathing efficiency. Moreover, the emerging popularity of non-invasive ventilation for improving breathing and oxygenation without the need for invasive procedures like intubation or mechanical ventilation in patients with severe COPD exacerbations, is expected to drive the chronic obstructive pulmonary disease market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the chronic obstructive pulmonary disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic obstructive pulmonary disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic obstructive pulmonary disease market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic obstructive pulmonary disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic obstructive pulmonary disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chronic obstructive pulmonary disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the chronic obstructive pulmonary disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chronic obstructive pulmonary disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chronic obstructive pulmonary disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (​2018-2034​) of chronic obstructive pulmonary disease across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of chronic obstructive pulmonary disease by age across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of chronic obstructive pulmonary disease by gender across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of chronic obstructive pulmonary disease by type across the seven major markets?
How many patients are diagnosed (​2018-2034​) with chronic obstructive pulmonary disease across the seven major markets?
What is the size of the chronic obstructive pulmonary disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of chronic obstructive pulmonary disease?
What will be the growth rate of patients across the seven major markets?

Chronic Obstructive Pulmonary Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chronic obstructive pulmonary disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic obstructive pulmonary disease market?
What are the key regulatory events related to the chronic obstructive pulmonary disease market?
What is the structure of clinical trial landscape by status related to the chronic obstructive pulmonary disease market?
What is the structure of clinical trial landscape by phase related to the chronic obstructive pulmonary disease market?
What is the structure of clinical trial landscape by route of administration related to the chronic obstructive pulmonary disease market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Chronic Obstructive Pulmonary Disease - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Chronic Obstructive Pulmonary Disease - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Chronic Obstructive Pulmonary Disease - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (​2018-2034​)
7.2.4 Epidemiology by Gender (​2018-2034​)
7.2.5 Epidemiology by Type (​2018-2034​)
7.2.6 Diagnosed Cases (​2018-2034​)
7.2.7 Patient Pool/Treated Cases (​2018-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (​2018-2034​)
7.3.4 Epidemiology by Gender (​2018-2034​)
7.3.5 Epidemiology by Type (​2018-2034​)
7.3.6 Diagnosed Cases (​2018-2034​)
7.3.7 Patient Pool/Treated Cases (​2018-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (​2018-2034​)
7.4.4 Epidemiology by Gender (​2018-2034​)
7.4.5 Epidemiology by Type (​2018-2034​)
7.4.6 Diagnosed Cases (​2018-2034​)
7.4.7 Patient Pool/Treated Cases (​2018-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (​2018-2034​)
7.5.4 Epidemiology by Gender (​2018-2034​)
7.5.5 Epidemiology by Type (​2018-2034​)
7.5.6 Diagnosed Cases (​2018-2034​)
7.5.7 Patient Pool/Treated Cases (​2018-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (​2018-2034​)
7.6.4 Epidemiology by Gender (​2018-2034​)
7.6.5 Epidemiology by Type (​2018-2034​)
7.6.6 Diagnosed Cases (​2018-2034​)
7.6.7 Patient Pool/Treated Cases (​2018-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (​2018-2034​)
7.7.4 Epidemiology by Gender (​2018-2034​)
7.7.5 Epidemiology by Type (​2018-2034​)
7.7.6 Diagnosed Cases (​2018-2034​)
7.7.7 Patient Pool/Treated Cases (​2018-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (​2018-2034​)
7.8.4 Epidemiology by Gender (​2018-2034​)
7.8.5 Epidemiology by Type (​2018-2034​)
7.8.6 Diagnosed Cases (​2018-2034​)
7.8.7 Patient Pool/Treated Cases (​2018-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (​2018-2034​)
7.9.4 Epidemiology by Gender (​2018-2034​)
7.9.5 Epidemiology by Type (​2018-2034​)
7.9.6 Diagnosed Cases (​2018-2034​)
7.9.7 Patient Pool/Treated Cases (​2018-2034​)

8 Chronic Obstructive Pulmonary Disease - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Chronic Obstructive Pulmonary Disease - Unmet Needs

10 Chronic Obstructive Pulmonary Disease - Key Endpoints of Treatment

11 Chronic Obstructive Pulmonary Disease - Marketed Products
11.1 List of Chronic Obstructive Pulmonary Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Incruse Ellipta (Umeclidinium) - GlaxoSmithKline
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Yupelri (Revefenacin) - Viatris/Theravance Biopharma
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Bevespi Aerosphere (Formoterol/glycopyrrolate) - AstraZeneca
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Duaklir Pressair (Aclidinium bromide/formoterol) - Covis Pharma
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Striverdi Respimat (Olodaterol) - Boehringer Ingelheim
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Chronic Obstructive Pulmonary Disease - Pipeline Drugs
12.1 List of Chronic Obstructive Pulmonary Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Ensifentrine - Verona Pharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Tezepelumab - Amgen/AstraZeneca
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Dupilumab - Regeneron/Sanofi
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 SELK2 - Tetherex Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 GSK3923868 - GlaxoSmithKline
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Chronic Obstructive Pulmonary Disease - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Chronic Obstructive Pulmonary Disease – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Chronic Obstructive Pulmonary Disease - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Chronic Obstructive Pulmonary Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Chronic Obstructive Pulmonary Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Chronic Obstructive Pulmonary Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Chronic Obstructive Pulmonary Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Chronic Obstructive Pulmonary Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Chronic Obstructive Pulmonary Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Chronic Obstructive Pulmonary Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Chronic Obstructive Pulmonary Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Chronic Obstructive Pulmonary Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Chronic Obstructive Pulmonary Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Chronic Obstructive Pulmonary Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Chronic Obstructive Pulmonary Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Chronic Obstructive Pulmonary Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Chronic Obstructive Pulmonary Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Chronic Obstructive Pulmonary Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Chronic Obstructive Pulmonary Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Chronic Obstructive Pulmonary Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Chronic Obstructive Pulmonary Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Chronic Obstructive Pulmonary Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Chronic Obstructive Pulmonary Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Chronic Obstructive Pulmonary Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Chronic Obstructive Pulmonary Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Chronic Obstructive Pulmonary Disease - Access and Reimbursement Overview

16 Chronic Obstructive Pulmonary Disease - Recent Events and Inputs From Key Opinion Leaders

17 Chronic Obstructive Pulmonary Disease Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Chronic Obstructive Pulmonary Disease Market – Strategic Recommendations

19 Appendix